Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Estrogens
  • Neoplasms, Hormone-Dependent
  • Nitriles
  • Progesterone
  • Triazoles

abstract

  • Patients originally randomly assigned to receive letrozole within 3 months of stopping tamoxifen did better than placebo patients in DFS and CLBC, despite 66% of placebo patients taking letrozole after unblinding.

publication date

  • May 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdm566

PubMed ID

  • 18332043

Additional Document Info

start page

  • 877

end page

  • 82

volume

  • 19

number

  • 5